Can a shorter bladder cancer treatment time cut side effects?
NCT ID NCT04701151
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether reducing the time BCG stays in the bladder (dwell-time) can lessen severe side effects in people with high-risk non-muscle invasive bladder cancer. About 314 patients from Nordic countries will either get the standard dwell-time or a shorter one based on their side effect severity. The goal is to help more patients complete their full treatment plan and lower the chance of cancer coming back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Bacillus Calmette Guerin (BCG)
What this could lead to
If it works, this could offer a way to manage severe side effects from BCG therapy, helping more patients finish their full treatment course and potentially reduce cancer recurrence.
What could go wrong
This is a phase 4 study focused on side effects, not on proving the treatment works better. Reducing dwell-time might not ease side effects for everyone, and it could still affect how well the BCG fights the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON MUSCLE INVASIVE BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aarhus University Hospital
Aarhus, Aarhus N, 8200, Denmark
-
Department of Urology, Aalborg University Hospital
Aalborg, 9100, Denmark
-
Department of Urology, Rigshospitalet
Copenhagen, 2100, Denmark
-
Herlev Hospital
Herlev, Denmark
-
Karolinska University Hospital
Stockholm, 141-86, Sweden
-
Landspitali University Hospital
Reykjavik, 101, Iceland
-
Odense University Hospital
Odense, 5000, Denmark
-
PO Sahlgrenska Universitetssjukhuset
Gothenburg, sw 413 45, Sweden
-
Regional Hospital Gødstrup
Herning, 7400, Denmark
-
Zealand University Hospital
Roskilde, 4000, Denmark
-
Örebro University Hospital
Örebro, 701 85, Sweden